Guided Therapeutics (GTHP) Non-Current Debt (2010 - 2025)
Guided Therapeutics (GTHP) reported Non-Current Debt of $23000.0 for Q4 2025, down 51.06% on a YoY basis from $47000.0 in Q4 2024, and down 20.69% sequentially from $29000.0 in Q3 2025.
Guided Therapeutics (GTHP) Non-Current Debt (2010 - 2025) Analysis & Trends
Guided Therapeutics (GTHP) has 16 years of Non-Current Debt data on file, last reported at $23000.0 in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Debt fell 51.06% year-over-year to $23000.0; the trailing twelve-month figure through Dec 2025 stood at $23000.0 (down 51.06% YoY), and the FY2025 full-year result was $23000.0, down 51.06% from the prior year.
- Non-Current Debt eased to $23000.0 in Q4 2025, from $29000.0 in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $787000.0 in Q3 2021 to a low of $22770.0 in Q1 2023.
- A 5-year average of $233219.8 and a median of $54784.5 in 2022 frame the typical range for Non-Current Debt.
- Across the five-year window, Non-Current Debt soared 2366.67% in 2021 and tumbled 94.91% in 2022, its largest moves.
- Tracing GTHP's Non-Current Debt over 5 years: stood at $592000.0 in 2021, then sank by 90.44% to $56569.0 in 2022, then soared by 66.44% to $94152.0 in 2023, then slumped by 50.08% to $47000.0 in 2024, then tumbled by 51.06% to $23000.0 in 2025.
- Business Quant data shows GTHP's Non-Current Debt at $23000.0 in Q4 2025, $29000.0 in Q3 2025, and $35000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 29.64 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 14.22 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 26.17 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 10.99 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 598.50 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | - |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 8.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 10.13 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 3.18 Bn |
| 10 | Guided Therapeutics | 21.96 Mn | 21.89 Mn | 458,000.00 | 23,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 23,000.00 |
| Sep 30, 2025 | 29,000.00 |
| Jun 30, 2025 | 35,000.00 |
| Mar 31, 2025 | 41,000.00 |
| Dec 31, 2024 | 47,000.00 |
| Sep 30, 2024 | 53,000.00 |
| Jun 30, 2024 | 59,000.00 |
| Mar 31, 2024 | 24,003.00 |
| Sep 30, 2023 | 94,152.00 |
| Jun 30, 2023 | 563,000.00 |
| Mar 31, 2023 | 22,770.00 |
| Dec 31, 2022 | 56,569.00 |
| Sep 30, 2022 | 590,000.00 |
| Jun 30, 2022 | 29,462.00 |
| Dec 31, 2021 | 592,000.00 |
| Sep 30, 2021 | 787,000.00 |
| Jun 30, 2021 | 579,000.00 |
| Mar 31, 2021 | 573,000.00 |
| Dec 31, 2020 | 24,000.00 |
| Sep 30, 2020 | 50,000.00 |